The S1103Y Cardiac Sodium Channel Variant Is Associated With Implantable Cardioverter-Defibrillator Events in Blacks With Heart Failure and Reduced Ejection Fraction

Albert Y. Sun, MD; Jason I. Koontz, MD, PhD; Svati H. Shah, MD, MHS; Jonathan P. Piccini, MD, MHS; Kent R. Nilsson, Jr, MD; Damian Craig, MS; Carol Haynes, AB; Simon G. Gregory, PhD; Patrick M. Hranitzky, MD; Geoffrey S. Pitt, MD, PhD

Background—Risk-stratifying heart failure patients for primary prevention implantable cardioverter-defibrillators (ICDs) remains a challenge, especially for blacks, who have an increased incidence of sudden cardiac death but have been underrepresented in clinical trials. We hypothesized that the S1103Y cardiac sodium channel SCN5A variant influences the propensity for ventricular arrhythmias in black patients with heart failure and reduced ejection fraction.

Methods and Results—Blacks (n=112) with ejection fractions <35% receiving primary prevention ICDs were identified from the Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository and followed for appropriate ICD therapy (either antitachycardia pacing or shock) for documented sustained ventricular tachycardia or fibrillation. The S1103Y variant was overrepresented in patients receiving appropriate ICD therapy compared with subjects who did not (35% versus 13%, P=0.03). Controlling for baseline characteristics, the adjusted hazard ratio using a Cox proportional hazard model for ICD therapy in Y1103 allele carriers was 4.33 (95% confidence interval, 1.60 to 11.73, P=0.01). There was no difference in mortality between carriers and noncarriers.

Conclusions—This is the first report that the S1103Y variant is associated with a higher incidence of ventricular arrhythmias in blacks with heart failure and reduced ejection fraction. (Circ Cardiovasc Genet. 2011;4:163-168.)

Key Words: heart failure ■ death ■ sudden ■ genetics ■ ion channels ■ race/ethnicity

African Americans disproportionately have heart failure, ventricular arrhythmias, and sudden cardiac death (SCD) when compared with whites.1-3 Although implantable cardioverter-defibrillators (ICDs) effectively reduce mortality from SCD in heart failure patients,4,5 the ability to identify prospectively the patients who will derive benefit from these therapies is lacking. Current guidelines, based on clinical trials, fail to identify the majority of patients who will have SCD.6 New risk stratification algorithms are urgently needed, especially for blacks, who have been underrepresented in clinical trials.

Clinical Perspective on p 168

Genetic-based risk stratification offers the potential for both identifying high-risk patients who do not qualify for primary prevention strategies and excluding low-risk individuals who do. Although a diverse array of genetic loci have been associated with SCD, ion channel genes are particularly intriguing candidates as they underlie the vast majority of inherited arrhythmias.7 Moreover, a sizable percentage of ion channel mutations only elicit a proarrhythmic phenotype in the setting of environmental stressors such as exposure to a QT-prolonging medication.8 Thus, we hypothesize that mutations in ion channels could contribute to the acquired arrhythmias in heart failure.

For blacks, the common variant S1103Y in the cardiac sodium channel gene SCN5A has been associated with a predisposition to acquired arrhythmias and was a candidate for testing our hypothesis. The S1103Y variant, found almost exclusively in people of African descent and present in 13% of blacks, has been associated in multiple studies with life-threatening arrhythmias in the setting of provocative environmental stimuli, such as QT-prolonging medications.9 In addition, this mutation has been associated with both sudden infant death syndrome10,11 and SCD in the presence of mild to moderate cardiomegaly.12 In the present report, we tested whether the S1103Y variant was associated with the occurrence of arrhythmias in blacks with heart failure and reduced ejection fraction.
Methods

Study Population
The Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository is a prospective, single-center repository that archives DNA, RNA, and protein samples obtained at the time of an electrophysiological evaluation or intervention. Demographic, laboratory, and cardiovascular risk factor data are collected at the time of ICD implantation. Device type was determined by the implanting operator and was not restricted by manufacturer. ICD programming and follow-up intervals were left to the discretion of the treating electrophysiologist. Between May 2005 and April 2008, 137 consecutive self-identified black patients aged 18 or older undergoing ICD placement for purposes of primary prevention with a left ventricular ejection fraction <35% were included. Twenty-three subjects were excluded because of insufficient clinical follow-up variables or insufficient DNA. Two were excluded because of suspected or confirmed inherited arrhythmia syndromes.

Follow-Up and Classification of Events
Patients were classified as having received appropriate ICD therapy if they had antitachycardia pacing or shock for documented sustained ventricular tachycardia or ventricular fibrillation. Patients who only received inappropriate ICD therapy or did not receive any antitachycardia pacing or shock were classified as having no appropriate ICD therapy. Events were adjudicated at the time of device interrogation by review of the treating electrophysiologist, who was blinded to the genotype. The research protocol was approved by the Duke University Institutional Review Board, and all patients consented to use of their samples for the EPGEN biorepository.

Statistical Analysis
Standard descriptive statistics were used, including percentages for discrete variables and means for continuous variables. Baseline characteristics were tested for significance, with the \( \chi^2 \) statistic for categorical variables and with the Student \( t \) test for continuous variables. Hardy-Weinberg equilibrium for the single nucleotide polymorphism (SNP) was tested using the \( \chi^2 \) Allele frequencies were compared between patients receiving appropriate ICD therapy and patients who did not receive appropriate ICD therapy using the Fisher exact test. Our primary analysis was a time-to-event analysis to assess the relationship between time to appropriate ICD therapy and genotype, and thus a life-table Kaplan-Meier survival analysis was performed using the log-rank statistic. Risk relationships were characterized as hazard ratios and 95% confidence intervals, generated with the use of a multivariable Cox proportional hazard model with covariates known to be associated with mortality and sudden cardiac death: age, sex, nonischemic cardiomyopathy, hyperlipidemia, hypertension, history of tobacco use, diabetes, and genotype. The assumption of proportional hazards for the regression model was not violated, as evidenced by the parallel nature of the plots of the cumulative hazard functions for the allele strata (data not shown). Further evidence of the validity of this assumption was provided by the lack of association of a time-varying covariate in the regression model (\( P = 0.92 \)). Two-sided probability values of <0.05 were considered statistically significant. All statistical analyses were performed with SAS version 9.2 (SAS Institute, Inc, Cary, NC).

Genotyping
DNA was extracted using PureGene (Genta Systems, Minneapolis, MN), following manufacturers standard protocol. Genotypes for rs7626962 (S1103Y) were determined using the 7900HT Taqman genotyping system (Applied Biosystems, Foster City, CA), which incorporates a standard PCR-based, dual-fluorophore, allelic discrimination assay. Assays were purchased from Applied Biosystems. QC samples, composed of 12 reference controls, were included in each quadrant of the plate. SNPs showing mismatches on QC samples were reviewed by an independent supervisor. The SNP was successfully genotyped for all of the individuals in the study. Error rate estimates for SNPs meeting QC benchmarks were <0.2%.

Results

Patient Characteristics
A total of 112 blacks who received ICDs for primary prevention were included. Mean follow-up was 865 days (interquartile range, 585 to 1131 days). The mean age was 62.8 years, and 34% of patients were women. Twenty-three patients (21%) received appropriate ICD therapy and 89 patients (79%) did not receive appropriate ICD therapy. Twelve of the 23 patients (52%) who received appropriate ICD therapy had ATP only as their classifying event. Baseline characteristics with respect to diabetes, tobacco use, hypertension, hyperlipidemia, atrial fibrillation, serum potassium level, New York Heart Association class, ejection fraction, maximum left ventricular wall thickness, or medications at time of enrollment did not differ significantly between patients that received appropriate ICD therapy and those who did not (Table 1). The corrected QT duration did not differ between the 2 groups (463 versus 465 ms, \( P = 0.41 \)). There was a higher percentage of patients classified as having nonischemic cardiomyopathy among those receiving appropriate ICD therapy (74% versus 48%, \( P < 0.02 \)).

Association of S1103Y and ICD Therapy
Genotyping revealed a Y1103 allele frequency of 0.09, with 92 patients homozygous for the S1103 allele (SS), 19 heterozygous (SY), and 1 homozygous for the Y1103 allele (YY) (online-only Data Supplement Table 1). There was no departure from Hardy-Weinberg equilibrium. \( \chi^2 \) analyses using a dominant model (at least 1 copy of the Y1103 allele) revealed a significant overrepresentation of the Y1103 allele in patients who received appropriate ICD therapy versus no appropriate ICD therapy, (8 of 23 [35%] versus 12 of 89 [13%], \( P = 0.03 \)) (Figure 1). The presence of the Y1103 allele correlated to an unadjusted odds ratio for appropriate ICD therapy of 3.42 (95% confidence interval [CI], 1.20 to 9.80; \( P = 0.02 \)). Although study-independent, genotype-blinded electrophysiologists adjudicated all ICD events, a sensitivity analysis excluding the 24 subjects who received only inappropriate ICD therapy was performed to account for possible errors in adjudication. Consistent with the primary analysis, this revealed an unadjusted odds ratio of 3.32 (95% CI, 1.09 to 10.07; \( P = 0.03 \)) for appropriate ICD therapy in Y1103 carriers. When analyzed by allele status, there was no significant difference in baseline characteristics (Table 2).

To assess the relationship between genotype and time to appropriate ICD therapy, a time-to-event survival analysis was performed. Kaplan-Meier curves diverged early and continued to diverge throughout the follow-up period showing a higher incidence of appropriate ICD therapy in Y1103 carriers (Figure 2, log-rank \( P = 0.01 \)). The mean time to appropriate ICD therapy for carriers was 59 days compared with 1057±36 days for noncarriers. Using a Cox proportional hazard model, carriers of the Y1103 allele had an age- and sex-adjusted hazard ratio of 3.50 (95% CI, 1.38 to 8.85; \( P = <0.01 \)) for ICD therapy compared with noncarriers (Table 3). An additional multivariable Cox proportional hazard model was performed adjusting for age and sex as well as nonischemic cardiomyopathy, hyperlipidemia, hyperten-
sion, history of tobacco use, and diabetes and resulted in a similar hazard ratio of 4.33 (95% CI, 1.60 to 11.73; \(P = 0.01\)) for appropriate ICD therapy in carriers of the Y1103 allele (Table 3). There were 4 deaths among patients who received appropriate ICD therapy (1 carrier of the Y1103 allele) and 15 deaths in those patients who did not receive appropriate ICD therapy (3 were carriers of the Y1103 allele). There was no association between all-cause mortality and Y1103 carrier status (\(P = 0.69\)).

### Discussion

To the best of our knowledge, this is the first report that the S1103Y variant in \textit{SCN5A} is associated with a higher incidence of ventricular arrhythmias in blacks with heart failure and reduced ejection fraction. Consistent with prior studies

### Table 1. Baseline Characteristics Stratified by ICD Therapy

<table>
<thead>
<tr>
<th>Characteristic*</th>
<th>Entire Cohort (n=112)</th>
<th>Appropriate ICD Therapy (n=23)</th>
<th>No Appropriate ICD Therapy (n=89)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>63 (12)</td>
<td>64 (9)</td>
<td>63 (13)</td>
</tr>
<tr>
<td>Men, n (%)</td>
<td>74 (66)</td>
<td>18 (78)</td>
<td>56 (63)</td>
</tr>
<tr>
<td>Medical history</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>History of nonischemic cardiomyopathy, n (%)†</td>
<td>60 (54)</td>
<td>17 (74)</td>
<td>43 (48)</td>
</tr>
<tr>
<td>History of diabetes, n (%)</td>
<td>57 (51)</td>
<td>11 (46)</td>
<td>46 (52)</td>
</tr>
<tr>
<td>Tobacco use, n (%)</td>
<td>59 (53)</td>
<td>12 (52)</td>
<td>47 (53)</td>
</tr>
<tr>
<td>History of hypertension, n (%)</td>
<td>101 (90)</td>
<td>22 (96)</td>
<td>79 (89)</td>
</tr>
<tr>
<td>History of hyperlipidemia, n (%)</td>
<td>81 (72)</td>
<td>18 (78)</td>
<td>63 (71)</td>
</tr>
<tr>
<td>History of atrial fibrillation, n (%)</td>
<td>51 (46)</td>
<td>9 (39)</td>
<td>42 (47)</td>
</tr>
<tr>
<td>NYHA class, mean (SD)</td>
<td>2.4 (0.6)</td>
<td>2.3 (0.7)</td>
<td>2.4 (0.6)</td>
</tr>
<tr>
<td>Echo parameters</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ejection fraction, mean (SD), %</td>
<td>25 (6)</td>
<td>24 (7)</td>
<td>25 (6)</td>
</tr>
<tr>
<td>Maximal LV wall thickness, mean (SD), cm</td>
<td>1.4 (0.3)</td>
<td>1.4 (0.3)</td>
<td>1.4 (0.3)</td>
</tr>
<tr>
<td>ECG parameters</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QTc, mean (SD), ms</td>
<td>464 (41)</td>
<td>463 (45)</td>
<td>465 (40)</td>
</tr>
<tr>
<td>Lab values</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum potassium at enrollment, mean (SD), mmol/L</td>
<td>4.2 (0.5)</td>
<td>4.1 (0.4)</td>
<td>4.2 (0.5)</td>
</tr>
<tr>
<td>Medication</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\beta)-blockers, n (%)</td>
<td>104 (93)</td>
<td>22 (96)</td>
<td>82 (92)</td>
</tr>
<tr>
<td>ACE inhibitors, n (%)</td>
<td>79 (70)</td>
<td>19 (82)</td>
<td>60 (67)</td>
</tr>
<tr>
<td>Diuretics, n (%)</td>
<td>91 (81)</td>
<td>19 (83)</td>
<td>72 (81)</td>
</tr>
<tr>
<td>Aspirin, n (%)</td>
<td>98 (88)</td>
<td>19 (83)</td>
<td>79 (89)</td>
</tr>
<tr>
<td>Digoxin, n (%)</td>
<td>28 (25)</td>
<td>6 (26)</td>
<td>22 (25)</td>
</tr>
</tbody>
</table>

ICD indicates implantable cardioverter-defibrillator; NYHA, New York Heart Association; LV, left ventricular; and ACE, angiotensin-converting enzyme.

\(\text{QTc} = \text{QT} / \sqrt{\text{RR}}\).

*\(P\leq 0.05\) for all variables except nonischemic cardiomyopathy.

†\(P=0.03\).

### Table 2. Clinical Characteristics and Events Stratified by Y1103 Allele Status

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Y1103 Carrier (n=20)</th>
<th>Y1103 Noncarrier (n=92)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appropriate ICD events, n (%)*</td>
<td>8 (40)</td>
<td>15 (16)</td>
</tr>
<tr>
<td>Nonischemic cardiomyopathy, n (%)</td>
<td>11 (55)</td>
<td>49 (53)</td>
</tr>
<tr>
<td>Ejection fraction, mean (SD)</td>
<td>26 (7)</td>
<td>24 (6)</td>
</tr>
<tr>
<td>QTc, mean (SD), ms</td>
<td>458 (47)</td>
<td>466 (40)</td>
</tr>
</tbody>
</table>

ICD indicates implantable cardioverter-defibrillator.

*\(P=0.03\).
that have implicated this common genetic variant with drug-induced long-QT syndrome (LQTS),9 SCD with cardiomegaly,12 and SIDS,10,11 this finding strengthens the evidence that this variant is proarrhythmic. The specific association between the S1103Y genotype and an increased risk of arrhythmia in heart failure may have particular significance as a novel risk factor for blacks.

Although the exact mechanism by which the S1103Y variant contributes to SCD in heart failure is unclear, we propose that heart failure is an environmental stressor for Y1103 carriers. Previously, Splawski et al9 demonstrated that the S1103Y variant causes a small, negative shift in sodium channel activation and increases peak transient current. An in silico–modeled ventricular action potential was not affected by these changes at baseline, but the addition of hERG blockade (eg, by a QT-prolonging medication) or acidosis significantly prolonged the action potential and promoted arrhythmia susceptibility.9,10 In our study population, we propose that the metabolic abnormalities and cellular derangements accompanying heart failure may serve as proarrhythmic stressors for Y1103 carriers. Splawski et al9 also found that decreased extracellular potassium prolonged action potentials generated with the Y1103 allele (compared with S1103 allele) and promoted arrhythmias. Although the serum potassium at the time of event was not universally available in our data set, we did not observe a significant difference in serum potassium level at the time of implant between patients receiving appropriate ICD therapy and those patients who did not.

We found that nonischemic cardiomyopathy was more prevalent in patients who received appropriate ICD therapy. The association of the Y1103 allele was independent of this finding. Because previous studies have not shown significant differences in the rates of ICD therapy or ventricular arrhythmias between ischemic or nonischemic origins of cardiomyopathy14 the difference may be secondary to sample size and should be investigated further during validation.

This association of S1103Y with arrhythmias in heart failure highlights increasing evidence for the general concept that certain acquired arrhythmias, such as drug-induced LQTS, manifest more commonly in individuals with a genetic predisposition; recent data suggest that up to 40% of drug-induced LQTS patients harbor otherwise clinically silent ion channel mutations.8 Arrhythmogenesis because of ion channel mutations can therefore be considered a “2-hit” model, in which specific triggers exacerbate the abnormal function of a mutant channel. For patients with an inherited arrhythmia syndrome, such as LQTS, the effects of the mutation on channel functional are more severe and require only mild arrhythmogenic triggers, such as bradycardia during sleep in LQT3 patients with SCN5A mutations.15 In contrast, acquired arrhythmias caused by mutations in the same ion channel loci occur with more severe environmental stressors (eg, QT-prolonging drugs or heart failure) on channels that are less functionally compromised.

The association of a genetic variant with life-threatening arrhythmias in heart failure may offer the possibility of genotype-specific risk-stratification strategies and targeted therapies. In the specific case of the S1103Y variant of SCN5A, which has been shown to increase the “late” or sustained Na+ current,9 consideration of the use of agents such as ranolazine that diminish the sustained current to reduce arrhythmic events is worthy of speculation.

The association of a genetic variant with life-threatening arrhythmias in heart failure may offer the possibility of genotype-specific risk-stratification strategies and targeted therapies. In the specific case of the S1103Y variant of SCN5A, which has been shown to increase the “late” or sustained Na+ current,9 consideration of the use of agents such as ranolazine that diminish the sustained current to reduce arrhythmic events is worthy of speculation.

There are several limitations to our study. Often used as a surrogate for SCD in heart failure, ICD therapy had previ-
ously been shown to occur more frequently than SCD in a heart failure population. Second, some patients were classified as having appropriate ICD therapy if the only ICD event recorded was appropriate ATP therapy. Although a well-validated method for termination of ventricular arrhythmias, individualized programming parameters could bias detection; a number of sustained ventricular tachycardia events could have been missed with conservative device programming. Most importantly, given the limited sample size, these findings must be validated in an independent cohort. Our attempts to identify one were unsuccessful because of the lack of well-phenotyped cohorts with sufficient black enrollment. This fact furthers strengthens the importance of minority recruitment and enrollment in clinical and genetic cardiovascular trials. Our finding is consistent with previous reports implicating the S1103Y variant with sudden cardiac death, sudden infant death syndrome, and drug-induced LQTS and thus enhances the growing body of literature demonstrating the inherent susceptibility to potentially lethal arrhythmias in Y1103 allele carriers.

In combination with traditional risk stratification tools such as ejection fraction, ECG analysis, and medical history, the addition of a genetic component could further strengthen the ability to identify heart failure patients at highest risk for sudden cardiac death and to identify mechanisms to prevent it. Given the relatively high prevalence of the S1103Y variant, this finding has a potentially large impact for the black community. The possible identification of a genetic contribution to sudden cardiac death in heart failure could establish a new paradigm and is an area fertile for further investigation.

Acknowledgments

Patient enrollment and data collection was assisted by Amy Hughes, Valerie Cumbea, and Anthony Waldron; genotyping was assisted by Karen Abramson and Elizabeth Grass, all of Duke University.

Sources of Funding

This study was supported in part by a grant from Medtronic, Inc., to Duke University as part of the Medtronic–Duke University Strategic Alliance (MEDUSA); a National Institutes of Health T32 training grant T32HL007101–35; the Greenfield Scholars Program (Dr Sun); National Alliance (MEDUSA); a National Institutes of Health T32 training grant T32HL007101–35; the Greenfield Scholars Program (Dr Sun); National Institutes of Health National Heart, Lung, and Blood Institute grants R01 HL71165 and R01 HL088089 (Dr Pitt); and an American Heart Association Established Investigator award (Dr Pitt).

Disclosures

Drs Sun, Koontz, Piccini, Nilsson, Craig, Haynes, Gregory, and Pitt received research grants from Medtronic Inc. $10 000; Dr Shah received a research grant from Medtronic Inc. $10 000 and other research support from Medtronic Inc. $10 000; Dr Hranitzky received a research grant from Medtronic Inc. $10 000 and other research support from Medtronic Inc. $10 000.

References


---

**CLINICAL PERSPECTIVE**

Sudden cardiac death (SCD) risk stratification for primary prevention implantable cardioverter-defibrillators (ICDs) is currently limited to reduced ejection fraction, yet the majority of people having SCD do not meet this criteria, nor do the majority of patients receiving primary prevention ICDs derive benefit from the device. In this report, we show that the S1103Y variant in the cardiac sodium channel gene, present in approximately 13% of blacks, is associated with a 3- to 4-fold increase in ICD “events” in patients with reduced ejection fraction. This genetic association is independent of traditional clinical risk factors for SCD. Identifying patients with this variant may potentially improve risk stratification for SCD in blacks, in whom there is a high prevalence of this variant.
The S1103Y Cardiac Sodium Channel Variant Is Associated With Implantable Cardioverter-Defibrillator Events in Blacks With Heart Failure and Reduced Ejection Fraction


Circ Cardiovasc Genet. 2011;4:163-168; originally published online April 15, 2011; doi: 10.1161/CIRCGENETICS.110.958652

Circulation: Cardiovascular Genetics is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 1942-325X. Online ISSN: 1942-3268

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circgenetics.ahajournals.org/content/4/2/163

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Genetics can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Genetics is online at:
http://circgenetics.ahajournals.org/subscriptions/